Last reviewed · How we verify
Phenoxymethylpenicillin
Phenoxymethylpenicillin is a Small molecule drug developed by Katarina Hedin. It is currently FDA-approved for Acute otitis media, Erysipelas, Fusospirochetal pharyngitis. Also known as: Penicillin V (PcV), Penicillin V, Primcillin, Marketing Authorisation Number PL; 04520/0005.
Phenoxymethylpenicillin, also known as penicillin V, is a small molecule inhibitor of bacterial penicillin-binding protein. It is used to treat bacterial infections such as strep throat, otitis media, and cellulitis, as well as to prevent rheumatic fever and infections following removal of the spleen.
At a glance
| Generic name | Phenoxymethylpenicillin |
|---|---|
| Also known as | Penicillin V (PcV), Penicillin V, Primcillin, Marketing Authorisation Number PL; 04520/0005, Weifapenin 650 mg, WEIFA, no. 100 |
| Sponsor | Katarina Hedin |
| Target | Bacterial penicillin-binding protein, Penicillin-binding protein 1A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Acute otitis media
- Erysipelas
- Fusospirochetal pharyngitis
- Gingivostomatitis
- Infection Prevention from Tooth Extraction
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Infective otitis media
- Pharyngitis
- Pneumococcal Acute Otitis Media
- Rheumatic Fever Prevention
- Scarlet fever
- Streptococcal tonsillitis
- Streptococcus pyogenes infection
- Upper Respiratory Pneumococcal Infection
- Upper Respiratory Streptococcal Infection
- Upper respiratory infection
Common side effects
- Nausea
- Vomiting
- Epigastric distress
- Diarrhea
- Black hairy tongue
- Skin eruptions
- Urticaria
- Laryngeal edema
- Anaphylaxis
- Fever
- Eosinophilia
- Hemolytic anemia
Key clinical trials
- GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial (PHASE2)
- The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D) (PHASE4)
- Addition of Probenecid to Penicillin-V Therapy (PHASE1, PHASE2)
- Sore Throat in Primary Care - a Comparison of Phenoxymethylpenicillin and No Antibiotic Treatment (PHASE4)
- Minimally Invasive Sensing of Beta-lactam Antibiotics (PHASE1)
- Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota (PHASE4)
- Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenoxymethylpenicillin CI brief — competitive landscape report
- Phenoxymethylpenicillin updates RSS · CI watch RSS
- Katarina Hedin portfolio CI
Frequently asked questions about Phenoxymethylpenicillin
What is Phenoxymethylpenicillin?
What is Phenoxymethylpenicillin used for?
Who makes Phenoxymethylpenicillin?
Is Phenoxymethylpenicillin also known as anything else?
What development phase is Phenoxymethylpenicillin in?
What are the side effects of Phenoxymethylpenicillin?
What does Phenoxymethylpenicillin target?
Related
- Target: All drugs targeting Bacterial penicillin-binding protein, Penicillin-binding protein 1A
- Manufacturer: Katarina Hedin — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Acute otitis media
- Indication: Drugs for Erysipelas
- Indication: Drugs for Fusospirochetal pharyngitis
- Also known as: Penicillin V (PcV), Penicillin V, Primcillin, Marketing Authorisation Number PL; 04520/0005, Weifapenin 650 mg, WEIFA, no. 100
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing